News
Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the ...
The regulatory body determined that PTC Therapeutics’ New Drug Application for vatiquinone did not provide sufficient ...
TipRanks on MSN15h
JPMorgan adds PTC Therapeutics to Analyst Focus List after selloff
JPMorgan added PTC Therapeutics (PTCT) to the firm’s Analyst Focus List while keeping an Overweight rating on the shares with a $68 price target ...
TipRanks on MSN15h
PTC Therapeutics price target lowered to $76 from $82 at BofA
BofA lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $82 and keeps a Buy rating on the shares after the FDA issued a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback